LATE-BREAKING DATA FROM ESOC2024: Clinical Consequences of Hematoma Expansion and Thrombotic Events in Patients with ICH Associated with Factor Xa-Inhibitor Treatment – Secondary Analysis from ANNEXA-I

May 13, 2024 | Antithrombotics

2) Our first-time expert author is #ANNEXa_I investigator David Seiffge MD @DavidSeiffge, Vascular neurologist at Inselspital Bern 🇨🇭#FOAMed #FOAMcc #neurotwitter #cardiotwitter #ICH @ESOStroke @WorldStrokeOrg pic.twitter.com/RDJPwWn6fb— cardio-met...

Albuminuria: The Canary in the Coal Mine of Kidney and Cardiorenal Disease

Apr 12, 2024 | CARDIORENAL

2) The program is intended for #HCPs & is supported by an independent educational grant from Bayer. Statement of accreditation and faculty disclosures at https://t.co/gvXca4GHMU. Follow this 🧵for 0.75hr 🆓 CE/#CMEcredit–all delivered right here on X!—...

ACUTE PSVT MANAGEMENT UPDATES, “LIVE” FROM ACC24

Apr 8, 2024 | Arrhythmia

2) Our expert faculty from here at #ACC24 is Narendra Singh MD @heartdrsingh, #cardiologist & faculty at both @MCG_AUG and College of Health Professions, Mercer University Atlanta. He is Director, Clinical Research at NSC Cardiology, Johns Creek, Georgia....

NOTABLE HIGHLIGHTS “LIVE” FROM ACC24: ADVANCES IN NON-STATIN LIPID THERAPY

Apr 8, 2024 | LIPIDS

2) Not all pts w/ #hyperlipidemia & associated #CV risk can tolerate #statins, & others are statin-refractory. Much research on non-statin alternatives. @DrMarthaGulati, #cardiologist @CedarsSinai is a leader in this space & is President of...

Code ICH: A Call to Action

Mar 17, 2024 | Antithrombotics

1b) @AnticoagPharmD is Systems Director of Anticoagulation Services and also is the Co-Chair of the @NATF Thrombosis Medical Advisory Board & the @AnticoagForum ACE committee. She will be discussing the very exciting #CodeICH project that launched with...